Archive \ Volume.12 2021 Issue 4

Diabetes Mellitus type 2: Management and follow up in Primary Health Care Center, Review Article

Ashraf Ali AlKinani , Ibrahim Mohammed Alkhrizi , Saleh Hamdan Alkathiri , Hani Lahk A Alzubaidi , Abdulrahman Ahmed Alghanmi , Abdulrahman Mohammed Alghanmi , Ibrahim Ahmed Alnashri , Alruwaili Amal Muhaysin B , Abdulrahman mohammad Alahmadi , Zainab Ali Alabdulmuhsin , Ayad Sultan Ayad Alosaimi , Salwa Mohammed Jubran Mahzari

Abstract

Diabetes mellitus is a worldwide epidemic, affecting around half a billion patients and these numbers are expected to grow within the next few years and decades, Placing a huge burden on the health system worldwide, this is because the chronic hyperglycemic state is associated with multiple long-term complications including micro and macrovascular complications in addition patients may develop acute complications such as Diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state, and hypoglycemia, which all may lead to fatal consequences. Our objective was to look into the literature concerning diabetes management and follow-up in particular type 2 PubMed database was used for articles selection, papers were obtained and reviewed. Management of diabetic patients should be individualized but the main principles of care are to achieve adequate glycemic control, through lifestyle modifications, pharmacological and surgical management, in addition to early identification and modification of cardiovascular risk factors that could contribute to developing atherosclerotic diseases one of the main causes of mortality, in addition to establishing scheduled follow-up appointments to screen for complication through physical examination, history taking and laboratory test.



How to cite:
Vancouver
AlKinani AA, Alkhrizi IM, Alkathiri SH, Alzubaidi HLA, Alghanmi AA, Alghanmi AM, et al. Diabetes Mellitus type 2: Management and follow up in Primary Health Care Center, Review Article. Arch Pharm Pract. 2021;12(4):49-53. https://doi.org/10.51847/mVmt9SdIfp
APA
AlKinani, A. A., Alkhrizi, I. M., Alkathiri, S. H., Alzubaidi, H. L. A., Alghanmi, A. A., Alghanmi, A. M., Alnashri, I. A., B, A. A. M., Alahmadi, A. M., Alabdulmuhsin, Z. A., et al. (2021). Diabetes Mellitus type 2: Management and follow up in Primary Health Care Center, Review Article. Archives of Pharmacy Practice, 12(4), 49-53. https://doi.org/10.51847/mVmt9SdIfp

Download Citation
References

1.        Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, et al. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017;66(2):241-55. doi:10.2337/db16-0806

2.        Galaviz KI, Weber MB, Straus A, Haw JS, Narayan KMV, Ali MK. Global Diabetes Prevention Interventions: A Systematic Review and Network Meta-analysis of the Real-World Impact on Incidence, Weight, and Glucose. Diabetes Care. 2018;41(7):1526-34. doi:10.2337/dc17-2222

3.        Green A, Hede SM, Patterson CC, Wild SH, Imperatore G, Roglic G, et al. Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia. 2021;64(12):2741-50. doi:10.2139/ssrn.3751311

4.        Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843

5.        Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137-88. doi:10.1152/physrev.00045.2011

6.        Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017;101(3):587-606. doi:10.1016/j.mcna.2016.12.011

7.        Pfeiffer AF, Klein HH. The treatment of type 2 diabetes. Dtsch Arztebl Int. 2014;111(5):69-81.

8.        Rodríguez-Gutiérrez R, Montori VM. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. Circ Cardiovasc Qual Outcomes. 2016;9(5):504-12. doi:10.1161/CIRCOUTCOMES.116.002901

9.        Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights. 2016;11:95-104. doi:10.4137%2FBMI.S38440

10.      Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650-64. doi:10.2337/dc12-1801

11.      Wei N, Zheng H, Nathan DM. Empirically establishing blood glucose targets to achieve HbA1c goals. Diabetes Care. 2014;37(4):1048-51. doi:10.2337/dc13-2173

12.      Raveendran AV, Chacko EC, Pappachan JM. Non-pharmacological Treatment Options in the Management of Diabetes Mellitus. Eur Endocrinol. 2018;14(2):31-9. doi:10.17925/EE.2018.14.2.31

13.      Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304-9. doi:10.1056/NEJM199307293290502

14.      Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes. 2013;62(12):3976-86. doi:10.2337/db13-1093

15.      Brown RJ, Wijewickrama RC, Harlan DM, Rother KI. Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes. Diabetes Technol Ther. 2011;13(4):457-60. doi:10.1089/dia.2010.0159

16.      Pala L, Dicembrini I, Mannucci E. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol. 2019;56(9):973-80. doi:10.1007/s00592-019-01326-5

17.      Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164(11):740-51. doi:10.7326/M15-2650

18.      Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019;8(2):156-64. doi:10.1007/s13679-019-00335-3

19.      Zhang K, Yang W, Dai H, Deng Z. Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis. Diabetes Res Clin Pract. 2020;160:108001. doi:10.1016/j.diabres.2020.108001

20.      van Dalem J, Brouwers MC, Stehouwer CD, Krings A, Leufkens HG, Driessen JH, et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ. 2016;354:i3625. doi:10.1136/bmj.i3625

21.      Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926-7. doi:10.1001/jama.2019.3805

22.      Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840-8. doi:10.5114/aoms.2015.53304

23.      Tran KL, Park YI, Pandya S, Muliyil NJ, Jensen BD, Huynh K, et al. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits. 2017;10(4):178-88.

24.      Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(2):200-7. doi:10.1111/dom.12802

25.      Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319(15):1580-91. doi:10.1001/jama.2018.3024

26.      Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68(5):557-67. doi:10.1111/ijcp.12361

27.      Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther. 2011;33(11):1609-29. doi:10.1016/j.clinthera.2011.09.028

28.      Lebovitz HE. Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep. 2019;19(12):151. doi:10.1007/s11892-019-1270-y

29.      Singh M, Kumar A. Risks Associated with SGLT2 Inhibitors: An Overview. Curr Drug Saf. 2018;13(2):84-91. doi:10.2174/1574886313666180226103408

30.      Saisho Y. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes? Diseases. 2020;8(2):14. doi:10.3390/diseases8020014

31.      Petznick A. Insulin management of type 2 diabetes mellitus. Am Fam Physician. 2011;84(2):183-90.

32.      Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-701. doi:10.2337/dci18-0033

33.      Howard-Thompson A, Khan M, Jones M, George CM. Type 2 Diabetes Mellitus: Outpatient Insulin Management. Am Fam Physician. 2018;97(1):29-37.

34.      Gagliardino JJ, Aschner P, Baik SH, Chan J, Chantelot JM, Ilkova H, et al. Patients' education, and its impact on care outcomes, resource consumption and working conditions: data from the International Diabetes Management Practices Study (IDMPS). Diabetes Metab. 2012;38(2):128-34. doi:10.1016/j.diabet.2011.09.002

35.      Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577-85. doi:10.1056/NEJMoa1200111

36.      Ilyas S, Al-Refai R, Maharjan R, Diaz Bustamante L, Ghattas KN, Khan S. Bariatric Surgery and Type 2 Diabetes Mellitus: Assessing Factors Leading to Remission. A Systematic Review. Cureus. 2020;12(8):e9973. doi:10.7759/cureus.9973

37.      Capodanno D, Angiolillo DJ. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation. 2016;134(20):1579-94. doi:10.1161/CIRCULATIONAHA.116.023164

38.      American Diabetes A. Standards of Medical Care in Diabetes-2021 Abridged for Primary Care Providers. Clin Diabetes. 2021;39(1):14-43. doi:10.2337/cd21-as01


 


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.